Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth ...

Bristol Myers Squibb has said it is the first life sciences company to buy a new AI supercomputing infrastructure blueprint ...

In what is thought to be South Korea's largest biopharma acquisition to date, Samsung Biologics has agreed to buy PolyPeptide ...

Three more biotechs have revealed their intentions to list on Nasdaq – BlossomHill, VogenX, and Latigo – as 2026 continues on ...

Venture financing for UK biotechs reached a five-year high in the second quarter of the year, with more than £2 billion ...

New community diagnostic centres, improved screening programmes and investment in technology are helping to catch the disease ...

Illumina has unveiled a database of genomic alterations, called the Billion Cell Atlas, that can be used to identify and validate drug targets and train AI models used in drug discovery. The first ...

pharmaphorum is your source for news and analysis to stay on top of happenings in the world of pharma. Founded in 2009, pharmaphorum’s mission has always been to educate, inform, engage, and connect ...

In this Q&A, Paolo Correale, SVP of global access and pricing at EVERSANA, and Alan Crowther, general manager, global pricing ...

Transmission electron microscope image of a thin section cut through an area of mammalian lung tissue. The high magnification image shows two mitochondria. People living with thymidine kinase 2 ...

Drug discovery firm Exscientia has claimed a world first after announcing that the first precision engineered drug generated by artificial intelligence (AI) is entering clinical trials. UK-based ...

Could there be a third big pharma acquisition this week? MSD is rumoured to be in talks to buy Revolution Medicines in a deal that could be worth up to $32 billion. The chatter – first reported by the ...